Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €1.24 EUR
Change Today +0.003 / 0.24%
Volume 528.5K
VSC On Other Exchanges
Symbol
Exchange
Xetra
OTC US
As of 4:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

4sc ag (VSC) Snapshot

Open
€1.27
Previous Close
€1.23
Day High
€1.38
Day Low
€1.22
52 Week High
07/28/14 - €1.53
52 Week Low
03/10/15 - €0.60
Market Cap
62.8M
Average Volume 10 Days
238.7K
EPS TTM
€-0.19
Shares Outstanding
50.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for 4SC AG (VSC)

Related News

No related news articles were found.

4sc ag (VSC) Related Businessweek News

No Related Businessweek News Found

4sc ag (VSC) Details

4SC AG researches and develops small-molecule drugs for the treatment of cancer and autoimmune diseases. The company operates through two segments, Development and Discovery & Collaborative Business. Its product portfolio in the area of autoimmune includes Vidofludimus, an orally administered small-molecule drug, which is in Phase II b clinical trial for the treatment of crohn’s diseases. The company’s product portfolio in the area of oncology comprises Resminostat, an oral pan-histone-deacetylase inhibitor, which is in Phase II and Phase I clinical trials for the treatment of liver cancer, hodgkin lymphoma, colorectal cancer, non-small-cell lung cancer, and solid tumors; 4SC-202, an epigenetic anti-cancer compound that is in Phase I clinical trials for the treatment of hematologic tumors; and 4SC-205, an anti-cancer compound, which is in Phase I clinical trials for the treatment of solid tumors. It also conducts research programs in the areas of cancer immunotherapy, cancer stem cells, epigenetics, cytokine modulation, and ion channel blockers for the treatment of autoimmune, inflammatory eye, and oncology diseases. The company was founded in 1997 and is headquartered in Martinsried, Germany.

Founded in 1997

4sc ag (VSC) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: €278.0K
Co-Founder, Chief Scientific Officer, Chief D...
Total Annual Compensation: €198.0K
Compensation as of Fiscal Year 2013.

4sc ag (VSC) Key Developments

4SC AG Announces Earnings Results for the Year Ended December 31, 2014

4SC AG announced earnings results for the year 2014. Revenue increased by 44% year on year to EUR 7.06 million compared to EUR 4.90 million a year ago. This positive revenue performance was driven by stable business with research collaborations at Group subsidiary 4SC Discovery GmbH and the delivery of the resminostat compound to the partner Yakult Honsha for clinical trials in Japan. LBIT was EUR 9.44 million compared to EUR 10.59 million a year ago. The loss for the period decreased by 8% to EUR 9.70 million compared to EUR 10.53 million a year ago. Loss per share improved by 10% to EUR 0.19 compared to EUR 0.21 a year ago, because in addition to the improved consolidated net loss there was also a higher average number of shares in financial year 2014 due to the conversion of convertible notes issued in March and September. This results in an average monthly outflow of cash from operations amounting to EUR 0.71 million compared to EUR 0.60 million per month.

4SC AG Mulls Funding

4SC AG (XTRA:VSC) is seeking funding. Enno Spillner, Chief Executive Office of 4SC, said in 4SC publishes results for financial year 2014, "To this end, we are negotiating with investors and potential partners for resminostat, but we also believe 4SC-205 and our second epigenetic compound 4SC-202 in particular have enormous future potential. In our work, we take comfort from the almost unanimous backing of our shareholders for the capital reduction and reverse stock split at our Extraordinary General Meeting held March 11, 2015, and the associated improvements to our future financing options on the capital market."

4SC AG, 2014 Earnings Call, Mar 25, 2015

4SC AG, 2014 Earnings Call, Mar 25, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSC:GR €1.24 EUR +0.003

VSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSC.
View Industry Companies
 

Industry Analysis

VSC

Industry Average

Valuation VSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.4x
Price/Book 28.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 4SC AG, please visit www.4sc.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.